Literature DB >> 9373248

High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice.

J L Villeval1, K Cohen-Solal, M Tulliez, S Giraudier, J Guichard, S A Burstein, E M Cramer, W Vainchenker, F Wendling.   

Abstract

To evaluate the effects of long-term, high-dose exposure to thrombopoietin (TPO), lethally irradiated mice were grafted with bone marrow cells infected with a retrovirus carrying the murine TPO cDNA. Mice were studied for 10 months after transplantation. In plasma, TPO levels were highly elevated (10(4) U/mL) throughout the course of the study. All mice developed a lethal myeloproliferative disorder evolving in two successive phases. During the first phase (7-9 weeks posttransplant), platelet and white blood cell (WBC) counts rose four- and ten-fold, respectively, whereas hematocrits decreased slightly to 29% +/- 3%. The WBC were mainly mature granulocytes, but myeloid precursor cells were invariably observed as well as giant platelets with an irregular granule distribution. The striking features were a massive hyperplasia of megakaryocytes and granulocytes in the spleen and bone marrow and a hypoplasia of erythroblasts in bone marrow. Total numbers of megakaryocyte colony-forming cell, burst-forming unit-erythroid, and granulocyte macrophage colony-forming cells were increased but colony-forming unit-erythroid numbers decreased. From 10 weeks posttransplant and thereafter, WBC, platelets, and red blood cell numbers declined dramatically. The absolute numbers of progenitor cells were very low in the spleen and bone marrow, but sharply increased in the blood and peritoneal cavity. Extramedullary hematopoiesis was observed in several organs. Histologic sections of the spleen and bones revealed severe fibrosis and osteosclerosis. The mean survival time was 7 months posttransplant and mice died with severe pancytopenia. Notably, two mice died between 3 and 4 months posttransplant with a leukemic transformation. This disorder was transplantable into secondary recipients who developed an attenuated form of the disease similar to the one previously described (Yan et al, Blood 86:4025, 1995). Taken together, our data show that high and persistent TPO production by transduced hematopoietic cells in mice results in a fatal myeloproliferative disorder that has a number of features in common with human idiopathic myelofibrosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9373248

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  87 in total

1.  Inositol polyphosphate 4-phosphatase type I regulates cell growth downstream of transcription factor GATA-1.

Authors:  P Vyas; F A Norris; R Joseph; P W Majerus; S H Orkin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  The zinc-finger proto-oncogene Gfi-1b is essential for development of the erythroid and megakaryocytic lineages.

Authors:  Shireen Saleque; Scott Cameron; Stuart H Orkin
Journal:  Genes Dev       Date:  2002-02-01       Impact factor: 11.361

3.  Distinct domains of the GATA-1 cofactor FOG-1 differentially influence erythroid versus megakaryocytic maturation.

Authors:  Alan B Cantor; Samuel G Katz; Stuart H Orkin
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

4.  C-Mpl Is Expressed on Osteoblasts and Osteoclasts and Is Important in Regulating Skeletal Homeostasis.

Authors:  Tomas E Meijome; Jenna T B Ekwealor; R Adam Hooker; Ying-Hua Cheng; Wendy A Ciovacco; Sanjeev M Balamohan; Trishya L Srinivasan; Brahmananda R Chitteti; Pierre P Eleniste; Mark C Horowitz; Edward F Srour; Angela Bruzzaniti; Robyn K Fuchs; Melissa A Kacena
Journal:  J Cell Biochem       Date:  2015-10-06       Impact factor: 4.429

5.  CD133 marks a stem cell population that drives human primary myelofibrosis.

Authors:  Ioanna Triviai; Thomas Stübig; Birte Niebuhr; Kais Hussein; Asterios Tsiftsoglou; Boris Fehse; Carol Stocking; Nicolaus Kröger
Journal:  Haematologica       Date:  2015-02-27       Impact factor: 9.941

Review 6.  Preclinical models for drug selection in myeloproliferative neoplasms.

Authors:  Niccolò Bartalucci; Costanza Bogani; Alessandro M Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 7.  GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy.

Authors:  Te Ling; John D Crispino; Maria Zingariello; Fabrizio Martelli; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2018-02-19       Impact factor: 2.929

8.  A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.

Authors:  Alessandro Pancrazzi; Paola Guglielmelli; Vanessa Ponziani; Gaetano Bergamaschi; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi
Journal:  J Mol Diagn       Date:  2008-07-31       Impact factor: 5.568

9.  Immature and mature megakaryocytes enhance osteoblast proliferation and inhibit osteoclast formation.

Authors:  Wendy A Ciovacco; Ying-Hua Cheng; Mark C Horowitz; Melissa A Kacena
Journal:  J Cell Biochem       Date:  2010-03-01       Impact factor: 4.429

10.  Involvement of integrins alpha(3)beta(1) and alpha(5)beta(1) and glycoprotein IIb in megakaryocyte-induced osteoblast proliferation.

Authors:  Justin M Lemieux; Mark C Horowitz; Melissa A Kacena
Journal:  J Cell Biochem       Date:  2010-04-01       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.